Dr. José Baselga Biography José Baselga Wiki
Memorial Sloan Kettering Cancer Center paid its top doctor José Baselga $ 1.5 million in severance pay after he resigned under fire for failing to disclose million dollar payments from drug and health companies in dozen of research articles he authored would have.
Dr. José Baselga resigned from Memorial Sloan Kettering in the context of the controversy in 2018.
New from @charlesornstein and me: Memorial Sloan Kettering paid Dr. José Baselga $1.5 million in severance after he resigned over failing to disclose industry ties in medical articles he wrote. https://t.co/tRsJZAdlrX
— Katie Thomas (@katie_thomas) December 22, 2020
Nonprofit Baselga paid more than $ 1.5 million
Recent IRS filings show that the nonprofit Baselga paid more than $ 1.5 million in severance payments in 2018 and 2019, according to the New York Times.
The hospital declined to comment on whether Baselga had received an additional severance payment in 2020.
A spokesman told the point of sale that the earlier payments were part of the hospital’s “contractual obligation” under the Baselga employment contract, but declined to elaborate on them.
Baselga is now an executive at the pharmaceutical company AstraZeneca, where he oversees the development of its cancer drugs. He also declined to comment.
Charitable organizations often enter into employment contracts with top civil servants who provide compensation upon their departure. These agreements can be difficult to break except in cases where a court has determined that there is something illegal.
However, the law requires institutions to disclose the nature of their senior civil servant severance payment arrangements on their IRS records.
The departure from Baselga in the fall of 2018 is said to have rocked Sloan Kettering, where he served as chief medical officer.
Baselga was considered one of the world’s top breast cancer doctors at the time and failed to disclose millions of dollars in payments from drug and healthcare companies. In doing so, the financial ties were removed from dozens of research articles written in publications such as the New England Journal of Medicine.
He has also held board memberships or advisory roles at a number of other companies, including Roche, was involved in startups that tested cancer therapies, and played a key role in developing breakthrough drugs that revolutionized breast cancer treatment, The Times, and ProPublica reported.
In a 2017 article, he positively assessed the results of two Roche clinical studies that many found disappointing, without revealing his ties to the company.
The Times reported that he had received $ 3 million in consulting fees from Roche in the previous four years.
Baselga said at the time that his failure to disclose relationships with Roche and at least a dozen companies was unintentional.
“I admit there have been inconsistencies, but it is,” he told the Times. “It’s not that I don’t appreciate the importance.”
The Baselga revelations resulted in a revision of Memorial Sloan Kettering’s relationship with the healthcare and pharmaceutical industries, as well as significant changes to its conflict of interest policy.
Memorial Sloan Kettering’s managing director, Dr. Craig B. Thompson, apologized to his staff for handling the Baselga exit in fall 2018 and told staff, “The events of the past few weeks have not been treated the way I would have liked. ‘
The then chairman of the board, Douglas A. Warner III, meanwhile, admonished Baselga, saying his “crossed lines” and “off the shelf” in dealing with for-profit companies, the Times reported.
While Baselga was officially stepping down from his post, Warner suggested that the departure was not voluntary, saying, “He left us no choice.”
Baselga, a prominent researcher, confirmed his errors in a letter of resignation, saying the controversy surrounding him had been “too distracting” which ultimately led to his decision to resign.
The doctor also resigned from the boards of drug maker Bristol-Myers Squibb and Varian Medical Systems, a manufacturer of radiation protection equipment, and the Cancer Journal, where he was an editor.
Memorial Sloane Kettering top executives are no longer allowed to serve on boards of directors of drug and health companies. Limitations have also been placed on how executives and top researchers can benefit from the work developed at the facility.
The hospital’s finances have reportedly been hit hard by the pandemic. A loss of $ 453 million was recorded in the first three quarters of 2020. During the same period in 2019, the hospital had a profit of $ 77 million.